You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 22, 2024

Details for Patent: 9,532,991


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 9,532,991
Title:Risperidone sustained release microsphere composition
Abstract:A risperidone sustained release microsphere formulation is provided. The microsphere formulation includes risperidone or 9-hydroxy risperidone or salts thereof, and a polymer blend having a first uncapped lactide-glycolide copolymer and a second uncapped lactide-glycolide copolymer, in which the first uncapped lactide-glycolide copolymer is a copolymer with a high intrinsic viscosity and the second uncapped lactide-glycolide copolymer is a copolymer with a low intrinsic viscosity. The sustained release micro sphere formulation according to an embodiment of the present disclosure is suitable for large-scale industrialized production with improved stability, the in vivo release behavior of which will not change after long-term storage.
Inventor(s):Sun Kaoxiang, Liang Rongcai, Wang Qilin, Wang Wenyan, Liu Wanhui, Li Youxin
Assignee:
Application Number:US15217696
Patent Claim Types:
see list of patent claims
 

Drugs Protected by US Patent 9,532,991

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Shandong Luye RYKINDO risperidone FOR SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR 212849-001 Jan 13, 2023 RX Yes No ⤷  Sign Up ⤷  Sign Up Y TREATMENT OF SCHIZOPHRENIA IN ADULTS ⤷  Sign Up
Shandong Luye RYKINDO risperidone FOR SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR 212849-002 Jan 13, 2023 RX Yes Yes ⤷  Sign Up ⤷  Sign Up Y TREATMENT OF SCHIZOPHRENIA IN ADULTS ⤷  Sign Up
Shandong Luye RYKINDO risperidone FOR SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR 212849-003 Jan 13, 2023 RX Yes No ⤷  Sign Up ⤷  Sign Up Y TREATMENT OF SCHIZOPHRENIA IN ADULTS ⤷  Sign Up
Shandong Luye RYKINDO risperidone FOR SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR 212849-004 Jan 13, 2023 RX Yes No ⤷  Sign Up ⤷  Sign Up Y TREATMENT OF SCHIZOPHRENIA IN ADULTS ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

International Family Members for US Patent 9,532,991

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Australia 2012248038 ⤷  Sign Up
Brazil 112013027235 ⤷  Sign Up
Canada 2832663 ⤷  Sign Up
China 103338752 ⤷  Sign Up
China 104127385 ⤷  Sign Up
European Patent Office 2701687 ⤷  Sign Up
European Patent Office 3199146 ⤷  Sign Up
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.